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LETTER TO THE EDITOR
The prediction of virulence based 
on presence of virulence genes in E. coli may not 
always be accurate
Trudy M Wassenaar1* and Florian Gunzer2
Abstract 
Now that microbial whole genome sequencing is in reach of many researchers, it is common to infer virulent proper-
ties of a given bacterial isolate based on the presence of virulence genes. However, this may lead to inaccurate pre-
sumptions of virulence. Using the findings of a recent publication (Da Silva Santos et al. Gut Pathog 7:2, 2015) where 
virulence was inferred from a genome sequence and subsequently confirmed by in vitro analysis, we present an 
alternative view on the case described in that publication. Our alternative view point, which is further substantiated 
by whole genome sequencing of probiotic E. coli strains, may contribute to a more balanced vision on the interac-
tions between pathogens and host.
Keywords: Virulence, E. coli, Whole Genome Sequencing, Pathogenicity
© 2015 Wassenaar and Gunzer. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Correspondence
Recently, Da Silva Santos and colleagues published a con-
tribution to Gut Pathogens entitled ‘Escherichia coli from 
Crohn’s disease patient displays virulence features of 
enteroinvasive (EIEC), enterohemorrhagic (EHEC) and 
enteroaggregative (EAEC) pathotypes’ [1]. In this publi-
cation, an interesting E. coli strain was described, origi-
nating from a biopsy from a Crohn’s disease (CD) patient. 
The strain was analyzed by in vitro virulence assays and 
the analysis was completed by a whole-genome sequence.
These facts were described: the CD patient under-
went terminal ileum resection. One particular E. coli 
strain was detected in all analyzed colonies, both from 
biopsies of the ileum and from stools. The bacteria were 
detected in an intestinal site where multiple erosions 
were observed. The isolated strain, named D92/09, was 
able to attach to and invade epithelial cells, although it 
was not a typical adherent and invasive E. coli (AIEC): it 
contained genetic markers that are more typical for diar-
rheagenic E. coli, namely those defining EHEC and EAEC 
pathotypes (specifically: presence of eae, stx1, aggR, sat, 
espC, tsh and vat). Further characterization confirmed 
adherent and invasive properties but only weak cytotoxic 
activity; cytotoxicity was stronger for internalized bacte-
ria. The complete genome sequence identified 97% iden-
tity to an atypical EHEC strain that had been responsible 
for a large outbreak of enteropathic hemolytic uremic 
syndrome (HUS) in Germany [1].
The authors conclude that “(…) the bacteria were 
detected in an intestinal site where multiple erosions 
were observed. While this observation cannot imply a 
causal relationship, an eventual involvement of the bac-
teria cannot be ruled out. (…) [The] possession of a diver-
sified virulence background like that of E. coli D92/09 
would represent an adaptive advantage within the aug-
mented bacterial population in this clinical condition [of 
CD]”.
Although this sounds altogether plausible, we would 
like to draw attention to a further fact, which sheds a dif-
ferent light on the findings. The patient is described as 
follows: “The studied E. coli was isolated in December 
2009 from stools and an ileum biopsy of a 51-year-old 
woman who attended the Endoscopy unit of the Univer-
sity Hospital of the Botucatu Medical School/UNESP-
SP, Brazil, for routine colonoscopy. The patient was 
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diagnosed about 1 year earlier with small bowel CD com-
plicated by an obstructive stenosis adjacent to the ileoce-
cal valve and subsequently submitted to a terminal ileum 
and cecum resection. The patient had no clinical symp-
toms (…)”.
Thus, the patient had undergone the surgery (termi-
nal ileum and cecum resection) to treat the obstructive 
stenosis, but the colonoscopy had been performed on 
a routine basis. If the biopsies had not been taken, this 
strain had probably not been detected. At the moment of 
colonoscopy, the patient was without symptoms; in other 
words, this invasive and weakly cytotoxic E. coli strain 
was present in biopsies, but it had not caused symptoms. 
This provides room for an alternative interpretation, 
namely that the immune system of this CD patient was 
quite capable to keep this presumably pathogenic E. coli 
in check, or, alternatively, that this strain was not as path-
ogenic as it appeared to be, as judged from its genetic 
content.
Whether a bacterial strain is pathogenic is not always 
easy to define, as has been pointed out before [2, 3]. The 
distinction between a pathogen and a commensal is not 
a sharp division, but rather a grey area, and this distinc-
tion has become even less clear with insights from whole-
genome sequencing [4]. Colonization by commensals can 
protect against pathogens, though the same bacteria can 
cause disease in particular circumstances, as observed 
with, for example, the skin commensals Staphylococ-
cus aureus and Propionibacterium acnes [5]. Likewise, 
colonization by probiotic yeasts is regarded as beneficial, 
but can, in particular cases, cause infections: fungemia 
caused by Saccharomyces cerevisiae and S. boulardii 
have both been described [6–8]. Whether the outcome 
of colonization is disease or a commensal relationship is 
defined by a combination of factors, of which the genetic 
properties of the bacteria are not the only ones: genetic 
and immunological factors of the host, as well as the 
presence of other microbiota are also contributing.
This discussion, which is not purely semantic, par-
ticularly applies to the species E. coli, which comprises 
commensal, beneficial (health promoting), as well as dis-
ease-causing strains. The genome of E. coli is highly vari-
able [9], and undergoes frequent horizontal gene transfer: 
the genome of strain D92/09 bore evidence of recent 
gene acquisition by phages and other mobile elements, as 
the authors pointed out [1]. The notion that pathogenic-
ity is a result of (virulence) gene acquisition has recently 
been countered with observations that pathogens often 
have reduced genomes, and virulence may result from 
loss of so-called antivirulence genes [10]. For instance, it 
has been demonstrated that in EAEC strains, expression 
of virulence genes is under control of regulator AggR, 
but in presence of antivirulence gene aar, a negative 
regulator, expression of aggR is down-regulated and vir-
ulence is reduced [11]. In view of the reported presence 
of aggR in strain D92/09, it would be interesting to see if 
aar is present as well, as this could explain the absence of 
symptoms in the patient.
Acknowledging that Da Silva Santos and colleagues 
have demonstrated (by PCR) presence of a number of 
well-established virulence genes in strain D92/09, we 
consider the presence of such genes not necessarily suf-
ficient to assume a pathogenic phenotype. The probiotic 
E. coli strain Nissle1917 and the lesser known strain ABU 
83972 are genetically very similar to uropathogenic E. coli 
strain CFT073: they share a large number of virulence 
genes and probably have a common ancestor [12]. This 
does not necessarily make these E. coli strains equally 
virulent: Nissle1917 (also known as EcN, trade name 
Mutaflor®) has GRAS status (generally recognized as safe) 
[13] and is classified as a Biosafety Level 1 organism by 
the Central Committee on Biological Safety (ZKBS) of 
the German Federal Office of Consumer Protection and 
Food Safety (BVL). Despite its classification and frequent 
use as a probiotic, including as treatment to maintain 
remission of ulcerative colitis [14], even E. coli Nissle 
1917 is, in exceptional conditions, able to cause disease. 
For instance, it caused sepsis in a preterm newborn when 
administered at day 15 post-partum for treatment of a 
viral enteric infection [15].
We recently characterized the genome of six E. coli 
strains which together form the probiotic product Sym-
bioflor 2®, each of which contained a number of viru-
lence genes, as reported by the software MvirDB [16] 
and VFDB [17], computer programs specifically designed 
to identify virulence genes from bacterial genome 
sequences. These programs not only reported a range 
of virulence genes in the probiotic E. coli genomes, but 
also in the genome of E. coli K-12 MG1655, which we had 
included as a control  [18]. Many of the identified viru-
lence genes would only be functional when present in 
a complete genetic locus, which was often not the case. 
However, such incompleteness of virulence loci was not 
documented in the output of these programs, which con-
siderably weakened the outcome of those analyses.
After correcting for completeness of loci, there 
remained a number of virulence genes that were clearly 
present in the six probiotic E. coli strains, including a 
complete hly locus encoding E. coli α-hemolysin in three 
of the strains [18]. Presence of this hly locus had been 
noted before, and the strains in question even express low 
levels of hemolysin [19]. Few data are available on pres-
ence of hemolysin in commensal E. coli strains, though 
anecdotal evidence suggests it is sometimes observed; 
older studies have reported that between 3.6 and 9.9% of 
enteric commensal isolates were haemolytic [20, 21]. A 
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recent volunteer study demonstrated that in particular the 
weakly haemolytic strains present in the probiotic prod-
uct colonized the human gut persistently [22]. Despite 
presence of hly and other virulence genes, the persistent 
colonization did not result in symptoms [22]. Although 
healthy volunteers were selected for this study, the pro-
biotic product has been on the market for decades, and 
it is likely that IBD or CD patients have been amongst its 
many users. Nevertheless, safety reports collected over a 
period of six years covering over two million treatments 
sold reported very few adverse effects, and none that 
would indicate invasive or systemic infection [18].
In conclusion, presence of virulence genes in E. coli 
is difficult to predict, and even when identified, with in 
vitro evidence for (weak) expression, this is not always 
sufficient to predict a virulent phenotype for a given 
strain. Whether, in the case of the CD patient described 
by Da Silva Santos and coworkers, E. coli strain D92/09 
should be considered pathogenic remains an open ques-
tion in our view.
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